PTC and Jazz Pharmaceuticals among latest firms to win EU backing for drugs

 

• PTC Therapeutics (NASDAQ:PTCT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed their drugs for marketing authorization.
• PTC Therapeutics said that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the marketing authorization application for Sephience to treat phenylketonuria.
• Jazz Pharmaceuticals said that CHMP recommended the marketing authorization for Zanidatamab as a treatment for adults with advanced or spread HER2-positive biliary tract cancer who have already had at least one prior treatment.

https://www.msn.com/en-us/money/markets/ptc-and-jazz-pharmaceuticals-among-latest-firms-to-win-eu-backing-for-drugs/ar-AA1DCTUv